AVALO THERAPEUTICS, INC. Selling, General and Administrative Expense
AVALO THERAPEUTICS, INC. (AVTX) reported Selling, General and Administrative Expense of $10.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2024-03-29
- AVALO THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2023-12-31 was $2.68M, a 9.56% decline year-over-year.
- AVALO THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2023-09-30 was $2.49M, a 24.18% decline year-over-year.
- AVALO THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2023-06-30 was $2.43M, a 12.82% decline year-over-year.
- AVALO THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2023-03-31 was $2.71M, a 76.82% decline year-over-year.
- AVALO THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $10.30M, a 50.27% decline from fiscal 2022.
- AVALO THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $20.71M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $5.17M derived: sum of 2 quarters · filed 2024-03-29 | $7.59M derived: sum of 3 quarters · filed 2024-03-29 | $10.30M 10-K · filed 2024-03-29 |
| 2023-09-30 | $2.49M 10-Q · filed 2023-11-09 | $4.92M derived: sum of 2 quarters · filed 2023-11-09 | $7.62M 10-Q · filed 2023-11-09 | $10.58M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | $2.43M 10-Q · filed 2023-08-03 | $5.13M 10-Q · filed 2023-08-03 | $8.09M derived: sum of 3 quarters · filed 2024-03-29 | $11.38M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | $2.71M 10-Q · filed 2023-05-04 | $5.67M derived: sum of 2 quarters · filed 2024-03-29 | $8.95M derived: sum of 3 quarters · filed 2024-03-29 | $11.73M derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $6.24M derived: sum of 2 quarters · filed 2024-03-29 | $9.03M derived: sum of 3 quarters · filed 2024-03-29 | $20.71M 10-K · filed 2024-03-29 |
| 2022-09-30 | $3.28M 10-Q · filed 2023-11-09 | $6.07M derived: sum of 2 quarters · filed 2023-11-09 | $17.75M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $2.78M 10-Q · filed 2023-08-03 | $14.47M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $11.68M 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $5.93M 10-Q · filed 2022-11-07 | $13.33M derived: sum of 2 quarters · filed 2022-11-07 | $18.68M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $7.40M 10-Q · filed 2022-08-04 | $12.75M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |